Therefore, many studies are focusing on the use of immunotherapy with immune checkpoint inhibitors (ICIs), such as those targeting PD-1/PD-L1 in HNSCC treatment. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.